Rani Therapeutics Holdings Stock Performance
| RANI Stock | USD 2.02 0.03 1.51% |
The company holds a Beta of 2.55, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rani Therapeutics will likely underperform. At this point, Rani Therapeutics has a negative expected return of -0.2%. Please make sure to check Rani Therapeutics' skewness, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Rani Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Rani Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
| Begin Period Cash Flow | 27.5 M |
Rani |
Rani Therapeutics Relative Risk vs. Return Landscape
If you would invest 296.00 in Rani Therapeutics Holdings on August 31, 2024 and sell it today you would lose (97.00) from holding Rani Therapeutics Holdings or give up 32.77% of portfolio value over 90 days. Rani Therapeutics Holdings is currently does not generate positive expected returns and assumes 9.825% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of stocks are less volatile than Rani, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rani Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rani Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rani Therapeutics Holdings, and traders can use it to determine the average amount a Rani Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0206
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RANI |
Estimated Market Risk
| 9.82 actual daily | 87 87% of assets are less volatile |
Expected Return
| -0.2 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Rani Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rani Therapeutics by adding Rani Therapeutics to a well-diversified portfolio.
Rani Therapeutics Fundamentals Growth
Rani Stock prices reflect investors' perceptions of the future prospects and financial health of Rani Therapeutics, and Rani Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rani Stock performance.
| Return On Equity | -2.25 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 69.62 M | ||||
| Shares Outstanding | 33.31 M | ||||
| Price To Book | 21.25 X | ||||
| Price To Sales | 313.17 X | ||||
| EBITDA | (65.28 M) | ||||
| Cash And Equivalents | 98.17 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 30.1 M | ||||
| Debt To Equity | 0.18 % | ||||
| Book Value Per Share | 0.49 X | ||||
| Cash Flow From Operations | (51.24 M) | ||||
| Earnings Per Share | (1.05) X | ||||
| Total Asset | 57.92 M | ||||
| Retained Earnings | (72.89 M) | ||||
About Rani Therapeutics Performance
By evaluating Rani Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Rani Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Rani Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Rani Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company was incorporated in 2012 and is headquartered in San Jose, California. Rani Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 114 people.Things to note about Rani Therapeutics performance evaluation
Checking the ongoing alerts about Rani Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rani Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rani Therapeutics generated a negative expected return over the last 90 days | |
| Rani Therapeutics has high historical volatility and very poor performance | |
| Rani Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (33.97 M) with profit before overhead, payroll, taxes, and interest of 2.72 M. | |
| Rani Therapeutics Holdings currently holds about 98.17 M in cash with (51.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Rani Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Rani Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rani Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Rani Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rani Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rani Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rani Therapeutics' stock. These opinions can provide insight into Rani Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Rani Stock analysis
When running Rani Therapeutics' price analysis, check to measure Rani Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rani Therapeutics is operating at the current time. Most of Rani Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rani Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rani Therapeutics' price. Additionally, you may evaluate how the addition of Rani Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |